Dateline City:
KENILWORTH, N.J. & SAN MATEO, Calif.
KENILWORTH, N.J. & SAN MATEO, Calif.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Afferent Pharmaceuticals announced today that the two companies have
signed a definitive agreement under which Merck will acquire this
privately held pharmaceutical company. Afferent Pharmaceuticals is a
leader in the development of therapeutic candidates targeting the P2X3
receptor for the treatment of common, poorly-managed, neurogenic
conditions.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Michael Close, 267-305-1211orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879orAfferentMedia:Susan Kinkead, 415-509-3610orInvestors:Dulce Dizon, 650-286-1276
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more